Abstract:Heterozygous germline mutations in PHOX2B, a transcriptional regulator of sympathetic neuronal differentiation, predispose to diseases of the sympathetic nervous system, including neuroblastoma and congenital central hypoventilation syndrome (CCHS). Although the PHOX2B variants in CCHS largely involve expansions of the second polyalanine repeat within the C-terminus of the protein, those associated with neuroblastic tumors are nearly always frameshift and truncation mutations. To test the hypothesis that the neuroblastoma-associated variants exert their effects through loss or gain of protein–protein interactions, we performed a large-scale yeast two-hybrid screen using both wild-type (WT) and six different mutant PHOX2B proteins against over 10 000 human genes. The neuronal calcium sensor protein HPCAL1 (VILIP-3) exhibited strong binding to WT PHOX2B and a CCHS-associated polyalanine expansion mutant but only weakly or not at all to neuroblastoma-associated frameshift and truncation variants. We demonstrate that both WT PHOX2B and the neuroblastoma-associated R100L missense and the CCHS-associated alanine expansion variants induce nuclear translocation of HPCAL1 in a Ca2+-independent manner, while the neuroblastoma-associated 676delG frameshift and K155X truncation mutants impair subcellular localization of HPCAL1, causing it to remain in the cytoplasm. HPCAL1 did not appreciably influence the ability of WT PHOX2B to transactivate the DBH promoter, nor did it alter the decreased transactivation potential of PHOX2B variants in 293T cells. Abrogation of the PHOX2B–HPCAL1 interaction by shRNA knockdown of HPCAL1 in neuroblastoma cells expressing PHOX2B led to impaired neurite outgrowth with transcriptional profiles indicative of inhibited sympathetic neuronal differentiation. Our results suggest that certain PHOX2B variants associated with neuroblastoma pathogenesis, because of their inability to bind to key interacting proteins such as HPCAL1, may predispose to this malignancy by impeding the differentiation of immature sympathetic neurons.

Super-enhancer-associated TTC8 Alters the Nucleocytoplasmic Distribution of PHOX2B and Activates MAPK Signaling in Neuroblastoma

CDK5RAP3 is a novel super-enhancer-driven gene activated by master TFs and regulates ER-Phagy in neuroblastoma

Super Enhancer-Mediated Upregulation Ofhjurppromotes Growth and Survival of T(4;14)-Positive Multiple Myeloma

Mutations That Disrupt PHOXB Interaction with the Neuronal Calcium Sensor HPCAL1 Impede Cellular Differentiation in Neuroblastoma

Super-enhancer-driven IRF2BP2 enhances ALK activity and promotes neuroblastoma cell proliferation

Super-enhancer-associated INSM2 Regulates Lipid Metabolism by Modulating Mtor Signaling Pathway in Neuroblastoma

Transcription factor 4 is a key mediator of oncogenesis in neuroblastoma by promoting MYC activity

Smoothened-Independent Activation of Hedgehog Signaling by Rearranged During Transfection Promotes Neuroblastoma Cell Proliferation and Tumor Growth

Tumor-suppressive disruption of cancer subtype-associated super enhancer circuits by small molecule treatment

HMGB3 is Associated With an Unfavorable Prognosis of Neuroblastoma and Promotes Tumor Progression by Mediating TPX2

MYC Drives a Subset of High-Risk Pediatric Neuroblastomas and is Activated Through Mechanisms Including Enhancer Hijacking and Focal Enhancer Amplification.

Comprehensive analysis identifies ubiquitin ligase FBXO42 as a tumor-promoting factor in neuroblastoma

Sox2 Promotes Tumorigenicity and Inhibits the Differentiation of I-Type Neuroblastoma Cells

SMAD9-MYCN positive feedback loop represents a unique dependency for MYCN-amplified neuroblastoma

METTL3-induced lncARSR aggravates neuroblastoma tumorigenic properties through stabilizing PHOX2B

An oncogenic super-enhancer formed through somatic mutation of a noncoding intergenic element

Conditional Activation of c-MYC in Distinct Catecholaminergic Cells Drives Development of Neuroblastoma or Somatostatinoma

TTF1 Suppresses Neuroblastoma Growth and Induces Neuroblastoma Differentiation by Targeting TrkA and the Mir-204/Trkb Axis

CCNB1IP1 stabilizes MYCN through suppression of Fbxw7-mediated degradation and facilitates the growth of MYCN-amplified neuroblastoma

JMJD6 is a Tumorigenic Factor and Therapeutic Target in Neuroblastoma

Super-enhancers delineate disease-associated regulatory nodes in T cells